Protocols
9 protocol(s) meet the specified criteria
Drug: ABRAXANE
Protocol No.TitleStatus
A091101Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) –a Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and NeckOpen
ALTERNATE/A011106ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III StudyOpen
CALGB30605A Phase II Study of Induction Chemotherapy followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer Open (affiliates only)
LCCC1330A Phase II study of carboplatin, paclitaxel and cetuximab for patients with recurrent or metastatic squamous cell carcinoma of the head and neckOpen
LCCC1612P53 mutational status and circulating free HPV DNA for the management of HPV-associated Oropharyngeal Squamous Cell Cancers Open
M14-360A Phase I Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung Cancer (NSCLC)Open
MSKCC-13-074Randomized phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) vs. bleomycin, etoposide and cisplatin (BEP) for patients with previously untreated intermediate- and poor- risk germ cell tumorsOpen
NRG-BR003-CIRBA Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High- Risk Node-Negative Triple-Negative Invasive Breast CancerOpen
TBCRC-030A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients with Triple Negative Breast Cancer Without Germline BRCA Mutations: Evaluating the Homologous Recombination Deficiency (HRD) BiomarkerOpen